2023 Year-End Summary | Breaking the Mold, Fostering Innovation
Release Date:
2024-01-29 13:53
Breaking the Mold·Innovation Born
Looking back on 2023, it was a year of breaking through adversity and forging ahead with determination.
Looking ahead to 2024, we will remain steadfast in our efforts and continue to forge ahead.
In the new year, we will continue to forge ahead with unwavering passion, together embracing the mountains and the seas.
On January 26, 2024, the 2023 year-end summary meeting of Hycells Biotechnology was held as scheduled near Lujiazui in Pudong.
In 2023, the industry as a whole faced widespread challenges, and our company’s core business experienced a severe downturn. Despite these headwinds, Hycells has nonetheless broken through the status quo by continuously innovating its technology platform and overcoming one obstacle after another. We extend our heartfelt gratitude to every team member for their tireless efforts and dedication—your agile responsiveness and highly efficient execution have enabled us to rise to one new challenge after another. We are also deeply thankful to both new and longstanding customers for their unwavering support and partnership throughout our journey.
Through diligent and unremitting efforts, we have reaped the rewards as expected. The steady progress of every individual at Hycells would not have been possible without the unwavering support of each and every team member. Over the past year, the company has also seen the emergence of one outstanding colleague after another. In recognition of their exceptional performance, Hycells honored these individuals across various departments and presented them with cash awards.
Who shines the brightest?
This year’s company annual gala was themed “Who Shines the Brightest?” With everyone pitching in and pooling their ideas, the atmosphere reached a thrilling climax.
The Marketing Department each received a gleaming spear or sword, along with a mask exuding icy, unyielding coolness. The Technology Department went all out by inviting heavyweight guests—the God of Wealth and the charming “Northeast Little Floral Coats”—to deliver heartwarming song-and-dance performances. Meanwhile, the Clinical Department rallied the entire team and their families to put on a lively and entertaining little-person dance. As for the Operations Department, it turned the stage into a runway show for Arabia’s richest tycoons, with dazzling golden ingots being generously tossed into the audience—so many that they literally blinded everyone present!
It’s truly hard to say who is the brightest star—every single one is equally dazzling. Between performances, the company also drew the annual grand prize, thoughtfully prepared for everyone.
Photos of team members at the annual meeting
Photos of the Annual Meeting Performance
Photo of lucky friends receiving their prizes
With the annual gala performances now over, the next stop was a group night cruise along the Huangpu River. As they savored Shanghai’s unique culinary delights, the group also took in the river’s breathtaking scenery. And while everyone was focused on the journey ahead, don’t forget to look up at the starry sky!
Night Cruise on the Huangpu River
2024 is sure to be another year of pressing forward under considerable pressure. Society must continue to advance, and technology must keep innovating—after all, innovation is the ladder that propels national progress. We hope that we will remain committed to exploration and continuous innovation, and collectively contribute our modest efforts to the development of the innovative pharmaceutical sector.
Hycells, together with all our team members, warmly wishes you an auspicious Year of the Dragon and success in all endeavors!
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board